DICOTnews March 2025
We have now surpassed 9,000 shareholders. This, along with the strong engagement we see, is truly gratifying. I would like to take this opportunity to warmly welcome all new shareholders. We promise to remain focused on maintaining strong momentum, delivering solid results, and ensuring open and transparent communication. Just like here in DICOTnews.
Elin Trampe, CEO of Dicot Pharma
Warrants now available for exercise
March 17 marks the start of the subscription period for the warrants included in the August rights issue. Major shareholders, and members of the board and management, have sent a strong signal by declaring their intention to subscribe for approximately 24%.
Phase 2a in full swing
Our efficacy study progresses exactly as planned. By early February, we had already dosed half of all participants. Results are expected to be reported in mid-2025.
Expert represents Dicot Pharma at ESSM
In February, we participated in Europe’s largest sexual medicine conference, where Professor François Giuliano, medical expert in our Phase 2a study, presented our study results and generating significant interest.
2024 Year-End Report now available
"With the excellent study results and the good financial situation, we can conclude that we are in a favorable position", writes Elin Trampe in the CEO statement of the recently published Year-End Report.
Swiss Nordic Bio 2025
Last week, Elin Trampe and CFO Björn Petersson participated in the annual Swiss Nordic Bio partnering conference in Zurich, where Elin also gave a well-attended presentation on Dicot Pharma.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.